Cargando…

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting

BACKGROUND: We monitored the evolution of markers of hepatitis B virus (HBV) infection in virologically suppressed HIV-positive patients switching to nucleoside reverse transcriptase inhibitor (NRTI)–sparing antiretroviral therapy within a randomized trial in Cameroon. METHODS: HBV surface antigen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdullahi, Adam, Fopoussi, Olga Mafotsing, Torimiro, Judith, Atkins, Mark, Kouanfack, Charles, Geretti, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201150/ https://www.ncbi.nlm.nih.gov/pubmed/30377627 http://dx.doi.org/10.1093/ofid/ofy251

Ejemplares similares

Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2019)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection
por: Zhang, Xiaoman, et al.
Publicado: (2019)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
por: Jiang, Bei, et al.
Publicado: (2022)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
por: Scheller, Laura, et al.
Publicado: (2021)

Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy
por: Liu, Yayun, et al.
Publicado: (2020)

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study
por: Parbie, Prince Kofi, et al.
Publicado: (2022)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy
por: Audsley, Jennifer, et al.
Publicado: (2016)

Editorial: serum HBV RNA biphasic decline in patients with HBeAg‐positive chronic hepatitis B treated with nucleos(t)ide analogues
por: Ding, Yang, et al.
Publicado: (2020)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
por: Xu, Xizhan, et al.
Publicado: (2017)

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
por: Wu, Lina, et al.
Publicado: (2021)

Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China
por: Zhao, Youyun, et al.
Publicado: (2016)

Differential response of HBV envelope-specific CD4(+) T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy
por: Li, Yongyin, et al.
Publicado: (2023)

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis
por: Stockdale, Alexander J, et al.
Publicado: (2018)

Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis
por: Zhao, Yuqing, et al.
Publicado: (2023)

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
por: Micán, Rafael, et al.
Publicado: (2022)

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection
por: Zhang, Hong, et al.
Publicado: (2020)

Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis
por: Chen, Mao-bing, et al.
Publicado: (2020)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients
por: Mahabadi, Mostafa, et al.
Publicado: (2013)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
por: Avihingsanon, Anchalee, et al.
Publicado: (2012)

HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination
por: Maasoumy, Benjamin, et al.
Publicado: (2020)

HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
por: Xie, Yandi, et al.
Publicado: (2021)

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
por: Mak, Lung-Yi, et al.
Publicado: (2023)

HBV influence on Response to Antiretroviral Therapy in Horizontally HIV-HBV Coinfected Patient during Early Childhood
por: Niculescu, Irina, et al.
Publicado: (2013)

Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model
por: Balogun, Kayode, et al.
Publicado: (2022)

HBV-Derived Synthetic Long Peptide Can Boost CD4(+) and CD8(+) T-Cell Responses in Chronic HBV Patients Ex Vivo
por: Dou, Yingying, et al.
Publicado: (2018)

Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients
por: Lai, Xiaoqin, et al.
Publicado: (2022)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Control of HBV infection in HIV/HBV co-infected patients treated with antiretroviral therapy – experience of Lodz Centre
por: Wlazłowska, Ewelina, et al.
Publicado: (2022)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog
por: Uchida, Yoshihito, et al.
Publicado: (2022)

Increased Expression of miR-487b Is Associated With Poor Prognosis and Tumor Progression of HBV-Related Hepatocellular Carcinoma
por: Cao, Xiangang, et al.
Publicado: (2020)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
por: Pastuch-Gawołek, Gabriela, et al.
Publicado: (2019)

Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients
por: Montanari, Noé R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vshgt9qjr3p5dh27407la4tnc3